Expertise in
41
conditions

Dr. Rami Komrokji

Hematology | Oncology
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Accepting New Patients
Offers Telehealth
Expertise in
41
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Rami Komrokji is a Hematologist and an Oncologist in Tampa, Florida. Dr. Komrokji is highly rated in 41 conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Sideroblastic Anemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Komrokji is currently accepting new patients.

His clinical research consists of co-authoring 383 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: January 26, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/1b Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: January 07, 2026
Intervention Type: Drug
Study Drug: Minnelide
Study Phase: Phase 1
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Drug, Biological
Study Drug: CD8-Depleted Donor Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Enrollment Status: Active_not_recruiting
Publish Date: October 31, 2025
Intervention Type: Drug
Study Drugs: Canakinumab, Darbepoetin Alfa
Study Phase: Phase 1/Phase 2
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Enrollment Status: Suspended
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Luspatercept
Study Phase: Phase 1/Phase 2
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: PRGN-3006 T Cells
Study Phase: Phase 1
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib
Study Phase: Phase 1/Phase 2
View 8 Less Clinical Trials

383 Total Publications

Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.
Plain language summary of IMerge, a Phase 3 study of imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia.
Journal: Future oncology (London, England)
Published: October 13, 2025
Similar Doctors
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4147
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Expertise in
34
conditions
Dr. Bijal Shah
Hematology | Oncology
Expertise in
34
conditions
Dr. Bijal Shah
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-820-1873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bijal Shah is a Hematologist and an Oncologist in Tampa, Florida. Dr. Shah is highly rated in 34 conditions, according to our data. His top areas of expertise are Mantle Cell Lymphoma (MCL), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Shah is currently accepting new patients.

Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology
Expertise in
41
conditions
Dr. Andrew Kuykendall
Hematology | Oncology

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-701-3769
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Kuykendall is a Hematologist and an Oncologist in Tampa, Florida. Dr. Kuykendall is highly rated in 41 conditions, according to our data. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration. Dr. Kuykendall is currently accepting new patients.

Frequently Asked Questions about Dr. Rami Komrokji

How do I make an appointment with Dr. Rami Komrokji?

You can book an appointment with Dr. Rami Komrokji by calling their office at 813-566-0119. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rami Komrokji a top-rated expert for Myelodysplastic Syndrome (MDS)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rami Komrokji is classified as an Elite expert for Myelodysplastic Syndrome (MDS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rami Komrokji specialize in?

While Dr. Rami Komrokji is a Hematology, they have specific expertise in Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Sideroblastic Anemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Rami Komrokji participate in research or clinical trials?

Yes. Dr. Rami Komrokji has published 383 articles and abstracts on conditions like Myelodysplastic Syndrome (MDS). You can view a list of Dr. Rami Komrokji's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rami Komrokji accept my insurance?

Dr. Rami Komrokji accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-566-0119 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Komrokji's expertise for a condition
ConditionClose
View All 16 Distinguished Conditions
View All 19 Advanced Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile